efinaconazole

(redirected from Jublia)

efinaconazole

(eff-in-a-kon-a-zole),

Jublia

(trade name)

Classification

Therapeutic: antifungals
Pharmacologic: triazoles
Pregnancy Category: C

Indications

Topical treatment of onychomycosis of the toenail.

Action

Inhibits synthesis of ergosterol, a component of fungal cell membranes.

Therapeutic effects

Resolution of toenail fungus.
Active against Tricyhophyton rubrum and Trychophyton mentagrophytes.

Pharmacokinetics

Absorption: Minimal systemic absorption follows application to toenails.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 29.9 hr.

Time/action profile

ROUTEONSETPEAKDURATION
Topical†unknownunknownunknown
† Prolonged treament is necessary due to need for treatment throughout growth of new toenails.

Contraindications/Precautions

Contraindicated in: None noted.
Use Cautiously in: Geriatric: Elderly patients may be more sensitive to drug effects; Obstetric: Use during pregnancy only if potential maternal benefit justifies potential risk to fetus; Lactation: Use cautiously if breastfeeding; Pediatric: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects

Local

  • application site dermatitis
  • application site pain
  • application site vesicles
  • ingrown toenail

Interactions

Drug-Drug interaction

None noted.

Route/Dosage

Topical (Adults) Apply to affected toenails once daily for 48 wk.

Availability

Solution: 10% in 4– and 8–mL bottles (with integrated flow-through applicator brush)

Nursing implications

Nursing assessment

  • Inspect involved areas of skin before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Indications)

Implementation

  • Topical: Apply to affected clean, dry toenails once daily for 48 wks with integrated flow-through brush applicator. Ensure toenail, toenail folds, toenail bed, hyponychium, and undersurface of toenail plate are completely covered. Solution is clear, colorless to pale yellow.

Patient/Family Teaching

  • Instruct patient to apply efinaconazole as directed for full course of therapy, even if feeling better. Emphasize the importance of topical use only, not for oral, ophthalmic or intravaginal use. Advise patient to wait at least 10 min after showering, bathing, or washing before applying. Efinaconazole is flammable; avoid use near heat or open flame.
  • Advise patient to report increased skin irritation (redness, itching, swelling) to health care professional.
  • Caution patient to avoid pedicures, nail polish, and cosmetic nail procedures during therapy.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Resolution of toenail fungus.
References in periodicals archive ?
Perrigo Company announced that Valeant Pharmaceuticals North America, Valeant Pharmaceuticals Ireland, Dow Pharmaceuticals Sciences and Kaken Pharmaceuticals initiated patent litigation on September 21, 2018 in the United States District Court for the District of New Jersey regarding Perrigo's Paragraph IV Abbreviated New Drug Application for efinaconazole topical solution 10%, asserting patents listed in the Orange Book for Jublia. This action formally initiates the litigation process under the Hatch-Waxman Act.
There are two newer topical medications, tavaborole (Kerydin) and efinaconazole (Jublia), but they are not covered under all insurance plans.
A third element in achieving treatment success is to use one of the newer topical agents: efinaconazole (Jublia) or tavaborole (Kerydin).
For example, the price of a year's supply of efinaconazole (Jublia), used to treat toenail fungus, is several thousand dollars.
The transfer will create 15 new engineering and production jobs and builds upon the transfer of Jublia production to Quebec earlier this year.
The transfer of Arestin will create 15 new engineering and production jobs and builds upon the transfer of Jublia production to Quebec earlier this year.
The ratings are supported by low exposure to patent cliffs, and good underlying prescription volumes of products like Jublia (antifungal) and Xifaxan for irritable bowel syndrome.
Its Jublia brand has advertised in each of the past two Big Games, much to the chagrin of ad watchers everywhere.
In April, the drug benefits manager is expected to begin a new program that limits the use of Valeant's Jublia, chief medical officer Dr.
has announced that it is moving its production of a popular antifungal called as Jublia from Japan to Canada, and has supplied its Laval, Que.
The seven new anti-infectives and their indications are dalbavancin (Dalvance) for treatment of skin infections caused by gram-positive organisms; efinaconazole (Jublia) for treatment of fungal infections of the toenails; miltefosine (Impavido) for treatment of visceral, cutaneous, and mucosal infections by various Leishmania species; oritavancin (Orbactiv) for skin infections caused by gram-positive bacteria; peramivir (Rapivab) for acute uncomplicated influenza; tavaborole (Kerydin) for treatment of fungal infections of the toenails; and tedizolid (Sivextro) for treatment of bacterial skin infections.
The seven new anti-infectives and their indications are dalbavancin (Dalvance) for treatment of skin infections caused by gram-positive organisms; efinaconazole (Jublia), for treatment of fungal infections of the toenails; miltefosine (Impavido) for treatment of visceral, cutaneous, and mucosal infections by various Leishmania species; oritavancin (Orbactiv) for skin infections caused by gram-positive bacteria; peramivir (Rapivab), for acute uncomplicated influenza; tavaborole (Kerydin) for treatment of fungal infections of the toenails; and tedizolid (Sivextro) for treatment of bacterial skin infections.